AKT1 and breast cancer: In addition, a prior study pointed out that inhibition of BTG2 expression in breast cancer could indirectly activate AKT and ERK-MAPK signaling pathways, thereby mediating the downstream effects of miR-25-3p and controlling disease progression (Chen et al. [23]).